Try one of the below options to narrow down your search.
 |
Documents may be browsed by date, eg; Today, June, 2013.
Past years can be browsed too, eg; 2012, 2011, 2010, 2009 ...
Documents can be searched within a period by browsing to the date and then using the search form; or by direct links, eg; Media releases from 2013
Document tags (shown below the document date, eg; Schedule, SAForms, consultation ...) have highest priority when search results are ranked, followed by title, abstract and full text of document.
Parentheses and the keywords and, or and not have special meaning in search terms. And is implicit and can be omitted; or must be specified.
Remember to group or statements with parentheses if they are beside and statements.
Search examples
- consultation
- Search for consultations
- media and not antibiotics
- Search for media related documents that don't mention antibiotics.
- (media or consultation) and vaccines
- Search for media releases and consultation documents mentioning vaccinations.
Search term:
2008 / 08 / 07
PHARMAC documents that matched your search:
13 June 2008 Herceptin CaTSoP minute
(3 pages, 64 KB)
2008/08/07
Cancer Treatments Subcommittee (CaTSoP) meeting held 13 June 2008 Trastuzumab for HER 2 positive early breast cancer 1. The Subcommittee considered further information from Roche Products NZ Limited for the use of 12 months’ trastuzumab in HER2-positive early breast cancer.…
4 July 2008 Herceptin PTAC minute
(9 pages, 127 KB)
2008/08/07
PTAC meeting held 4 July 2008 (minutes for web publishing) PTAC minutes are published in accordance with the following definitions from the PTAC Guidelines 2002: ““Minute” means that part of the record of a PTAC or Sub-committee meeting (including meetings…
Appendix Eight: detail of updates to clinical inputs for cost utility analysis
(33 pages, 372 KB)
2008/08/07
APPENDIX EIGHT DETAIL OF UPDATES TO CLINICAL INPUTS FOR COST UTILITY ANALYSIS Revised and updated clinical issues relevant to further cost utility analysis (CUA) for 12 months adjuvant trastuzumab (sequential and concurrent regimens) are as follows: 1. Disease progression of…
Appendix Nine: Updated* trastuzumab (Herceptin) clinical trial summaries**
(1 page, 64 KB)
2008/08/07
Appendix Nine: Updated* trastuzumab (Herceptin) clinical trial summaries** Sequential treatment trials, long duration (12 month)1 regimens HERA N9831 Arm B PACS043 Patient Numbers Observation: 1,693 Trastuzumab (1 yr): 1,694 1 Trastuzumab (2 yr): 1,694 Observation: 979 Trastuzumab: 985 Observation: 268…
Appendix Seven: Relevant minutes of clinical advisory committees meetings since February 2007
(13 pages, 259 KB)
2008/08/07
Appendix Seven: Relevant minutes of clinical advisory committees meetings since February 2007 Appendix One to TAR75b included the relevant minutes of the clinical advisory committees to February 2007. The Cancer Treatments Subcommittee of PTAC (CaTSoP) considered the trasuzumab for HER2…
Further Supplementary Technology Assessment Report No. 75c
(34 pages, 401 KB)
2008/08/07
PART 3 Further Supplementary Technology Assessment Report No. 75c 12 month trastuzumab (Herceptin) treatment in HER-2 positive early breast cancer, compared with 9 week concurrent treatment (supplement to TAR 75 of August 2006 and its supplementary TAR 75b of April…
Herceptin – a summary of the evidence at August 2008
(15 pages, 199 KB)
2008/08/07
Herceptin (trastuzumab) is a relatively new monoclonal antibody treatment developed to treat HER2 positive breast cancer...
Herceptin – questions and answers
(3 pages, 127 KB)
2008/08/07
Herceptin Questions and Answers 7 August 2008 Is Herceptin funded in New Zealand? Yes. New Zealanders continue to have fully funded access to an effective and full course of Herceptin treatment for HER2-positive early breast cancer – concurrent 9 week…
Notification letter August 2008
(2 pages, 168 KB)
2008/08/07
7 August 2008 Notification of a decision regarding the funding of 12 months treatments with trastuzumab (Herceptin) for HER2-positive early breast cancer Further to our 5 May 2008 consultation, the PHARMAC Board, at its 30 July 2008 meeting, decided to…
Pharmacology and Therapeutics Advisory Committee (PTAC) Member - closes 29 August 2008
(1 page, 136 KB)
2008/08/07
Pharmacology and Therapeutics Advisory Committee Application for PTAC Membership PHARMAC is the government agency responsible for ensuring New Zealanders have access to a wide range of affordable medicines. PHARMAC makes a vital contribution to New Zealand’s health outcomes. The Pharmacology…
